PD-1/PD-L1-IN-23 |
| Catalog No.GC64855 |
PD-1/PD-L1-IN-23 est un inhibiteur puissant et oralement actif de PD-1/PD-L1. PD-1/PD-L1-IN-23 est un promédicament ester de L7. L7 est un dérivé de benzo[c][1,2,5]oxadiazole et biologiquement évalué comme inhibiteur de PD-L1. PD-1/PD-L1-IN-23 affiche des effets antitumoraux significatifs dans des modèles tumoraux de souris syngéniques et humanisées PD-L1.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2597056-04-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
PD-1/PD-L1-IN-23 is a potent and orally active inhibitor of PD-1/PD-L1. PD-1/PD-L1-IN-23 is an ester prodrug of L7. L7 is a benzo[c][1,2,5]oxadiazole derivative and biologically evaluated as inhibitors of PD-L1. PD-1/PD-L1-IN-23 displays significant antitumor effects in tumor models of syngeneic and PD-L1 humanized mice[1].
[1]. Liu L, et al. Syntheses, Biological Evaluations, and Mechanistic Studies of Benzo[c][1,2,5]oxadiazole Derivatives as Potent PD-L1 Inhibitors with In Vivo Antitumor Activity. J Med Chem. 2021;64(12):8391-8409.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *